Novartis (VTX:NOVN)

Novartis est née de la fusion de Ciba-Geigy et Sandoz en 1996.  La société dont le siège est situé à Bâle est le 3rd largest pharmaceutical group in the world, the 2nd largest producer of generic drugs and holds 6% of the global vaccine market. The stock is making its debut this week in our portfolio, en même temps que Rock, suite à notre souci de diversification currencies and our resolutions from 2011. Novartis owns many of the qualities we look for in a great dividend payer and the title is listed in CHF on the SMI, which makes it possible to reduce overexposure to the dollar. Nevertheless, the "youth" of the company and its dividend hardly holds up to comparison with the leading names in our portfolio, such as Procter & Gamble Or Johnson & Johnson. Novartis is therefore the equivalent of an excellent hope of a football team, a youngster full of potential that must be kept close at hand and monitored. Our algorithm sets him as a "hold", behind McDonald, but well placed taking into account his relative youth. To date, we have therefore not taken a direct position on Novartis.

THE dividend yield sur le  long terme est correct, à 3%. La société a increased its distributions in recent years at an interesting annual rate of 15,62%. Le taux de distribution s'élève à 45%, ce qui laisse une bonne marge de manoeuvre à Novartis en cas de passage difficile. La volatility est également attrayante, avec 11.91%.